Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Teva Pharmaceutical Industries's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $7,506 Mil. Teva Pharmaceutical Industries's Total Assets for the quarter that ended in Dec. 2023 was $43,479 Mil.
Therefore, Teva Pharmaceutical Industries's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.17.
The historical rank and industry rank for Teva Pharmaceutical Industries's Equity-to-Asset or its related term are showing as below:
TEVA'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17 Med: 0.24 Max: 0.55
Current: 0.17
During the past 13 years, the highest Equity to Asset Ratio of Teva Pharmaceutical Industries was 0.55. The lowest was 0.17. And the median was 0.24.
TEVA's Equity-to-Asset is ranked worse than 86.02% of 1087
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs TEVA: 0.17
Teva Pharmaceutical Industries Equity-to-Asset Historical Data
The historical data trend for Teva Pharmaceutical Industries's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Teva Pharmaceutical Industries Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Equity-to-Asset
0.24
0.20
0.22
0.18
0.17
Teva Pharmaceutical Industries Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Equity-to-Asset
0.18
0.18
0.16
0.17
0.17
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries Equity-to-Asset Distribution
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Teva Pharmaceutical Industries's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Teva Pharmaceutical Industries Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TEVA has been successfully added to your 